Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Alzheimer's drugs take a new tack.

Callaway E.

Nature. 2012 Sep 6;489(7414):13-4. No abstract available.

PMID:
22962697
2.

Alzheimer's research. Stopping Alzheimer's before it starts.

Miller G.

Science. 2012 Aug 17;337(6096):790-2. doi: 10.1126/science.337.6096.790. No abstract available. Erratum in: Science. 2012 Nov 2;338(6107):604.

PMID:
22903991
3.

Antibody drugs for Alzheimer's show glimmers of promise.

Reardon S.

Nature. 2015 Jul 30;523(7562):509-10. doi: 10.1038/nature.2015.18031. No abstract available.

PMID:
26223602
4.

Perspective: prevention is better than cure.

Gandy S.

Nature. 2011 Jul 13;475(7355):S15. doi: 10.1038/475S15a. No abstract available.

PMID:
21760576
5.

Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.

Rygiel K.

Indian J Pharmacol. 2016 Nov-Dec;48(6):629-636. doi: 10.4103/0253-7613.194867. Review.

PMID:
28066098
6.

US government sets out Alzheimer's plan.

Wadman M.

Nature. 2012 May 22;485(7399):426-7. doi: 10.1038/485426a. No abstract available.

PMID:
22622544
7.

Bapineuzumab in Alzheimer's disease: where now?

Wilcock GK.

Lancet Neurol. 2010 Feb;9(2):134-6. doi: 10.1016/S1474-4422(09)70359-X. No abstract available.

PMID:
20129159
8.

Genentech's Alzheimer's antibody trial to study disease prevention.

Garber K.

Nat Biotechnol. 2012 Aug;30(8):731-2. doi: 10.1038/nbt0812-731. No abstract available.

PMID:
22871696
9.

Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Who may benefit from disease-modifying studies in Alzheimer's disease?

Gauthier S, Poirier J.

Alzheimers Dement. 2009 Mar;5(2):147-8. doi: 10.1016/j.jalz.2009.01.007. No abstract available.

PMID:
19328447
10.

Drugs: a tangled web of targets.

Gravitz L.

Nature. 2011 Jul 13;475(7355):S9-11. doi: 10.1038/475S9a. No abstract available.

PMID:
21760583
11.

Preventing Alzheimer's disease.

Selkoe DJ.

Science. 2012 Sep 21;337(6101):1488-92.

PMID:
22997326
12.

Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.

Imbimbo BP, Ottonello S, Frisardi V, Solfrizzi V, Greco A, Seripa D, Pilotto A, Panza F.

Expert Rev Clin Immunol. 2012 Feb;8(2):135-49. doi: 10.1586/eci.11.93. Review.

PMID:
22288451
13.

Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.

Donohue MC, Gamst AC, Aisen PS.

Alzheimers Dement. 2011 Mar;7(2):245-6; author reply 247-9. doi: 10.1016/j.jalz.2010.12.013. No abstract available.

PMID:
21414558
14.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

Salloway S, Sperling R, Brashear HR.

N Engl J Med. 2014 Apr 10;370(15):1460. No abstract available.

PMID:
24724181
15.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

de la Torre JC.

N Engl J Med. 2014 Apr 10;370(15):1459-60. doi: 10.1056/NEJMc1402193#SA2. No abstract available.

PMID:
24716689
16.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

Laske C.

N Engl J Med. 2014 Apr 10;370(15):1459. doi: 10.1056/NEJMc1402193#SA1. No abstract available.

PMID:
24716688
17.

Unraveling the tangled brain of Alzheimer's.

Wolfson W.

Chem Biol. 2008 Feb;15(2):89-90. doi: 10.1016/j.chembiol.2008.02.002. No abstract available.

PMID:
18291309
18.

Life imitates art: anti-amyloid antibodies and inflammatory cerebral amyloid angiopathy.

Greenberg SM, Frosch MP.

Neurology. 2011 Mar 1;76(9):772-3. doi: 10.1212/WNL.0b013e31820e7bce. No abstract available.

PMID:
21357829
19.

Noncholinergic treatment options for Alzheimer's disease.

Sano M.

J Clin Psychiatry. 2003;64 Suppl 9:23-8. Review.

PMID:
12934971
20.

Preventing cognitive decline in preclinical Alzheimer's disease.

Riedel WJ.

Curr Opin Pharmacol. 2014 Feb;14:18-22. doi: 10.1016/j.coph.2013.10.002. Epub 2013 Nov 13. Review.

PMID:
24565007

Supplemental Content

Support Center